logo

Clinical Trial Calendar

Share SHARE
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q2 2017
ARCA biopharma, Inc.
Interim analysis of phase 2b efficacy data of Gencaro (GENETIC-AF)
Atrial Fibrillation
Q2 2017
CAPRICOR THERAPEUTICS, INC.
6-month topline data from Phase I/II trial of CAP-1002 (HOPE)
Duchenne muscular dystrophy
Q2 2017
Paratek Pharmaceuticals, Inc.
Top-line data of Phase 3 study of Omadacycline
Community Acquired Bacterial Pneumonia (CABP)
Q2 2017
Aerie Pharmaceuticals, Inc.
Topline 90-day efficacy data from 2nd phase 3 trial of Roclatan (Mercury 2)
To lower intraocular pressure in patients with glaucoma
Q2 2017
Galapagos NV..
Topline data from phase 2a study of GLPG1690 (FLORA)
Idiopathic pulmonary fibrosis
Q2 2017
Summit Therapeutics plc
Initial data from phase 2 trial of Ezutromid (PhaseOut DMD)
Duchenne muscular dystrophy
Q2 2017
Summit Therapeutics plc
Initial F3 24-week muscle biopsy data from Phase 2 proof of concept clinical trial of Ezutromid
Duchenne muscular dystrophy
Q2 2017
Cellceutix Corp
CTIX.OB
Topline data from phase 2b trial of Prurisol
Moderate to severe plaque psoriasis
Late Q2 2017
Nuvo Research Inc.
Topline results from Phase 3 trial of Pennsaid 2%
acute ankle sprains
Q2 2017
Portola Pharmaceuticals Inc.
Resubmit AndexXa BLA
For patients treated with a Factor Xa inhibitor when reversal of anticoagulation is needed
Q2 2017
Zogenix, Inc.
Topline data from phase 3 study of ZX008 (Study 1501)
Dravet Syndrome
Q2 2017
Zogenix, Inc.
Topline data from phase 3 study of ZX008 (Study 1502)
Dravet Syndrome
Q2 2017
Neothetics Inc
Topline data from phase 2 study of modified formulation of LIPO-202
submental fat reduction.
Q2 2017
VistaGen Therapeutics Inc
Topline results from NIMH-sponsored Phase 2a study of AV-101
major depressive disorder
Q2 2017
Jazz Pharmaceuticals plc
Topline results from phase 3 study of JZP-110
excessive sleepiness associated with narcolepsy
Mar 2017
22nd Century Group Inc.
Completion of phase 3 study of SPECTRUM tobacco
harm caused by smoking
Mid Feb 2017
Biota Pharmaceuticals Inc.
Topline data from phase 2b trial of Vapendavir (SPIRITUS)
Adult asthmatics with symptomatic human rhinovirus
Q1 2017
Ardelyx, Inc
Results from 1st phase 3 trial of Tenapanor
Hyperphosphatemia in ESRD patients
Q1 2017
Alcobra Ltd.
Data from 2nd phase 3 study of Metadoxine Extended Release (MEASURE)
Adults with ADHD
Q1 2017
Nivalis Therapeutics, Inc.
Data from 2nd phase 2 trial of Cavosonstat (N91115)
Cystic fibrosis
2017
MERRIMACK PHARMACEUTICALS, INC.
Results from phase 2 study of ONIVYDE
Previously untreated front-line metastatic pancreatic cancer
2017
MERRIMACK PHARMACEUTICALS, INC.
Results from phase 2 study of MM-302 (HERMIONE)
HER2-positive metastatic breast cancer
1H 2017
pSivida Limited
Submit NDA for Medidur
Posterior uveitis.
Early 2017
Karyopharm Therapeutics Inc.
Top-line data from Phase 2b study of Selinexor (SADAL study)
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
Q1 2017
GW Pharmaceuticals PLC
GWPH, GWP.L
Data from phase 2 study of CBDV
Partial-onset epilepsy